AroCell AB (AROC) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 2.39%, its profits have risen by 14.3%

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

SEK 104 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.24

Return on Equity

-26.26%

Price to Book

0.69

Revenue and Profits:

Net Sales:

10 Million

(Quarterly Results - Jun 2025)

Net Profit:

-15 Million

Total Returns

Total Returns (Price + Dividend)

Company does not have enough history

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

121.24%

EBIT Growth (5y)

-19.08%

EBIT to Interest (avg)

-49.56

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.43

Sales to Capital Employed (avg)

0.37

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.93

EV to EBIT

-0.93

EV to EBITDA

-0.93

EV to Capital Employed

0.87

EV to Sales

0.79

PEG Ratio

Dividend Yield

ROCE (Latest)

-93.97%

ROE (Latest)

-49.00%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Sideways

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Mildly Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -33.99% vs -0.65% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -21.14% vs -36.67% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "10.10",
          "val2": "15.30",
          "chgp": "-33.99%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-14.80",
          "val2": "-11.70",
          "chgp": "-26.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-14.90",
          "val2": "-12.30",
          "chgp": "-21.14%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,461.50%",
          "val2": "-765.30%",
          "chgp": "-69.62%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 33.49% vs 16.22% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 28.50% vs 0.00% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "57.40",
          "val2": "43.00",
          "chgp": "33.49%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.70",
          "val2": "-14.90",
          "chgp": "88.59%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-42.40",
          "val2": "-59.30",
          "chgp": "28.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-781.30%",
          "val2": "-1,403.70%",
          "chgp": "62.24%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

10.10

15.30

-33.99%

Operating Profit (PBDIT) excl Other Income

-14.80

-11.70

-26.50%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-14.90

-12.30

-21.14%

Operating Profit Margin (Excl OI)

-1,461.50%

-765.30%

-69.62%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is -33.99% vs -0.65% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -21.14% vs -36.67% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

57.40

43.00

33.49%

Operating Profit (PBDIT) excl Other Income

-1.70

-14.90

88.59%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-42.40

-59.30

28.50%

Operating Profit Margin (Excl OI)

-781.30%

-1,403.70%

62.24%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 33.49% vs 16.22% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 28.50% vs 0.00% in Dec 2023

All Annual Results

Company CV

About AroCell AB

AroCell AB

Pharmaceuticals & Biotechnology

AroCell publ AB is a Sweden-based diagnostic Company engaged in the development of markers for determination of cell growth (TK 210) and apoptosis. The Company's principal product candidate, TK-immuno/hem, is a test for monitoring and follow up of blood cancer. The test is based on a patented technology, which have already been evaluated in an early product prototype ELISA method. Apart from that, the Company develops a marker for solid tumor cancer disease. The AroCell cooperates with partners within development, production and sales.

Company Coordinates

Company Details

Uppsala Business Park, Virdings alle 32 B UPPSALA None : 754 50

Tel: 46 18 503020

https://www.arocell.com/

Registrar Details